Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Prostatic Neoplasms

abstract

  • Docetaxel and (153)Sm-EDTMP can be combined safely at full doses over repeated cycles. Responses were seen in the small group of patients with taxane-resistant disease tested. The optimal phase II doses for patients with taxane-na├»ve disease may differ from those optimal for patients with taxane-resistant disease.

publication date

  • May 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2684850

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.4164

PubMed ID

  • 19364960

Additional Document Info

start page

  • 2436

end page

  • 42

volume

  • 27

number

  • 15